Whole-Body MRI in the Evaluation of Pediatric Malignancies
- Compare non-inferior diagnostic performance of whole-body MRI (i.e., combination of
turbo short-tau inversion-recovery (STIR) and out-of-phase imaging) vs conventional
imaging (i.e., the combination of chest CT scan, scintigraphy [bone, gallium,
meta-iodobenzylguanidine (MIBG), or optional fludeoxyglucose F 18 positron emission
tomography (FDG-PET)] and abdominal/pelvic CT scan/MRI as indicated) for detecting
distant metastases for use in staging common tumors in pediatric patients.
- Determine the incremental benefit of adding out-of-phase T1-weighted gradient-recalled
echo imaging to turbo STIR for detecting distant disease in these patients.
- Determine, preliminarily, the relative accuracies of FDG-PET, whole-body MRI, and a
combination of FDG-PET and whole-body MRI in detecting stage IV disease in these
- Determine the effects of multiple factors, including cancer type, site of primary
tumor, and patient age, on diagnostic accuracy of whole-body MRI in these patients.
- Determine the interobserver variability associated with interpreting whole-body MRI
exams for detecting distant metastases in these patients.
OUTLINE: This is a multicenter study.
Patients undergo conventional MRI, CT scan, and/or scintigraphy (e.g., bone,
meta-iodobenzylguanidine [MIBG], or gallium) and experimental whole-body MRI sequences.
Patients may optionally undergo fludeoxyglucose F18 positron emission tomography (FDG-PET).
Patients with a lesion (or lesions) detected on whole-body MRI or FDG-PET at initial staging
that are not confirmed by biopsy or other conventional imaging studies at staging repeat
standard imaging at 3- to 6-month follow-up.
Patients with an abnormality that is considered highly suspicious for a metastasis or when
biopsy proof of that metastasis is obtained receive treatment at the discretion of the
Patients are followed annually for 3 years.
PROJECTED ACCRUAL: A total of 226 patients (45 with neuroblastoma, 54 with rhabdomyosarcoma,
27 with other sarcoma, and 100 with lymphoma) will be accrued for this study within 1 year.
Masking: Open Label, Primary Purpose: Diagnostic
Marilyn J. Siegel, MD
Mallinckrodt Institute of Radiology at Washington University Medical Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|
|Children's Hospital of Philadelphia||Philadelphia, Pennsylvania 19104|
|Vanderbilt-Ingram Cancer Center||Nashville, Tennessee 37232-6838|
|Holden Comprehensive Cancer Center at University of Iowa||Iowa City, Iowa 52242-1002|
|Nemours Children's Clinic||Jacksonville, Florida 32207|
|Children's Memorial Hospital - Chicago||Chicago, Illinois 60614|
|St. Jude Children's Research Hospital||Memphis, Tennessee 38105-2794|
|Hollings Cancer Center at Medical University of South Carolina||Charleston, South Carolina 29425|
|UCSF Helen Diller Family Comprehensive Cancer Center||San Francisco, California 94115|
|Children's Hospital Center for Cancer and Blood Disorders||Aurora, Colorado 80045|
|AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus||Atlanta, Georgia 30322|
|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School||New Brunswick, New Jersey 08903|
|Riley's Children Cancer Center at Riley Hospital for Children||Indianapolis, Indiana 46202-5225|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|
|University of Miami Sylvester Comprehensive Cancer Center - Miami||Miami, Florida 33136|
|Mallinckrodt Institute of Radiology at Washington University Medical Center||St. Louis, Missouri 63110|
|Hasbro Children's Hospital||Providence, Rhode Island 02903|